Overactive bladder(OAB)
Conditions
Interventions
OAB-CL Drug Treatment Group 1:None
OAB-CL Drug Treatment Group 2:None
OAB-CL Laparoscopic Cholecystectomy (LC) Group:None
OAB-CL Combined Drug Therapy Group:None
Sponsors
Department of Urology, Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
All
Age
26 Years to 78 Years
Inclusion criteria
Inclusion criteria: 1. Patients with CL combined with OAB (OAB-CL); 2. Patients were seen between January 1, 2020 and December 31, 2024; 3. OAB-CL patients underwent laparoscopic cholecystectomy (LC) and underwent urodynamic examination before and after LC, as well as completed the OABSS and ICIQ-SF questionnaires.
Exclusion criteria
Exclusion criteria: 1. Patients with stress urinary incontinence; 2. Patients with vesicovaginal fistula; 3. Patients with urethrovaginal fistula; 4. Patients with cerebral hemorrhage, cerebral infarction, or mental disorders; 5. Patients with neurogenic bladder.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Demographic characteristics: gender, age, ethnicity, family history of cancer;Clinical symptom characteristics of gallstone with overactive bladder;Blood biochemical laboratory tests: liver function, renal function, urinalysis, peripheral white blood cell count, neutrophil count, monocyte count, lymphocyte count, platelet count, and albumin concentration;Imaging data: including urological ultrasound, abdominal ultrasound, urodynamic studies, and cystoscopy;Therapeutic efficacy of clinical behavioral and pharmacological treatments for overactive bladder (including solifenacin and mirabegron); | — |
Countries
China
Contacts
Public ContactChen Zongping
Affiliated Hospital of Zunyi Medical University
Outcome results
None listed